Mesoblast is a biotechnology business based in Australia. Mesoblast shares (MSB) are listed on the Australian Securities Exchange (ASX) and all prices are in Australian dollars. Mesoblast has a trailing 12-month revenue of around $7.5 million. If you're looking to buy shares, check out the steps below.
To buy shares listed in Australia such as Mesoblast, you'll need to sign up to a broker with access to the ASX. Our table can help you compare share trading platforms and choose. Then follow these steps.
Our top pick for
Best for beginner
Our top pick for
Education & learning
Our top pick for
Australian stocks
| 52-week range | $0.255 - $1.3511 |
|---|---|
| 50-day moving average | $0.5159 |
| 200-day moving average | $0.4332 |
| Target price | $1.6 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-0.13 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. However, this is not a recommendation. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Historical closes compared with the last close of A$0.915
| 1 week (2024-04-17) | 22.00% |
|---|---|
| 1 month (2024-03-25) | 177.27% |
| 3 months (2024-01-25) | 245.28% |
| 6 months (2023-10-25) | 164.39% |
| 1 year (2023-04-24) | -2.52% |
|---|---|
| 2 years (2022-04-22) | -13.84% |
| 3 years (2021-04-23) | -53.83% |
| 5 years (2019-04-24) | -37.94% |
| Revenue TTM | $7.5 million |
|---|---|
| Gross profit TTM | $-47,421,000 |
| Return on assets TTM | -5.61% |
| Return on equity TTM | -14.49% |
| Profit margin | 0% |
| Book value | 0.501 |
| Market capitalisation | $1 billion |
TTM: trailing 12 months
We're not expecting Mesoblast to pay a dividend over the next 12 months.
Mesoblast's shares were split on a 135:128 basis on 4 December 2023. So if you had owned 128 shares the day before the split, the next day you would own 135 shares. This wouldn't directly have changed the overall worth of your Mesoblast shares – just the quantity. However, indirectly, the new 5.2% lower share price could have impacted the market appetite for Mesoblast shares which in turn could have impacted Mesoblast's share price.
Over the last 12 months, Mesoblast's shares have ranged in value from as little as $0.255 up to $1.3511. A popular way to gauge a stock's volatility is its "beta".
Beta measures a share's volatility in relation to the market. The market (AU average) beta is 1, while Mesoblast's is 2.593. This would suggest that Mesoblast's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.
AMP Ltd Preferred
AUD104.55
ANZ Group Holdings Ltd. Pfd.
AUD103.35
Macquarie Bank Ltd Pref
AUD106.27
Macquarie Group Ltd Pref C
AUD102.80
Macquarie Group Ltd Pref
AUD105.50
Macquarie Group Preferred
AUD102.66
Macquarie Group Limited
AUD105.62
Suncorp Group Ltd Pref
AUD100.61
Westpac Banking Corp Pref
AUD102.76
Everything we know about the Sun Silver IPO, plus information on how to buy in.
Everything we know about the Tasmea Limited IPO, plus information on how to buy in.
Steps to owning and managing Far Northern Resources shares.
Commodity ETFs can be used to hedge against inflation. Here's what they do, why they should be on your watchlist and how they can help your portfolio.
Looking for the best performing stocks in Australia? We update this list weekly.
Steps to owning and managing Gol Linhas Aéreas Inteligentes SA shares from Australia.
Trade ASX stocks and ETFs with a $2 brokerage fee and a low minimum investment of just $10.
These ETFs have the lowest fees on the market, but does that make them the best?
You've heard of CommSec but how does it stack up to the likes of IG, CMC Invest and other players in the market?
Westpac Share Trading allows you to take control of your investments. Find out if its right for you.